Actavis is nearing a deal to acquire Allergan in a tie-up that would likely be the year’s largest and could help shield the Botox maker from hostile suitor Valeant.

If Actavis were allowed to discontinue sales of an older Alzheimer’s pill and steer patients toward a newer version in order to blunt generic competition, the move could cost Medicare Part D as ...

A U.S. appeals court on Thursday upheld three Tris Pharma Inc patents covering a form of its ADHD drug Quillivant, rejecting a challenge from Teva Pharmaceuticals-owned generic drugmaker Actavis ...

Actavis said its new once-a-day Namenda XR has "significant advantages over twice-a-day Namenda that are particular meaningful for Alzheimer's patients and their caregivers." ...

So Actavis pivoted, announcing that they would be yanking Namenda IR from the market, forcing Alzheimer’s patients to switch to the new XR product, or forego their medication.

Actavis stock rose 2% to 247.94. Allergan climbed 5% to 209. Allergan's board maintained all along that Valeant's offer "grossly undervalues" the company, which has achieved a strong IBD EPS Rank ...

Irish pharmaceutical company Actavis will buy Allergan, the maker of Botox, for $219 per share in cash and stock, the company said in a press release. Actavis' CEO Brent Saunders will lead the ...

Actavis and Allergan entered into a confidentiality agreement the day after a California federal court ruled that Ackman could vote his shares at a Dec. 18 special shareholders’ meeting ...

Actavis will pay $26.04 plus 0.3306 share per Forest Labs share. That's equal to $92.65 as of Tuesday's close, following Actavis' 5% gain to 201.47. Forest Labs shot up 27.5% to 91.04.

Commentary 'Actavis' and Reverse-Payments Suits in the Third Circuit After Five Years For over 20 years, purportedly anticompetitive patent-litigation settlement agreements between rival branded ...